10-Q: Aethlon Medical Reports Second Quarter 2025 Financial Results and Provides Business Update

Aethlon Medical reports a net loss of $5.37 million for the six months ended September 30, 2024, while advancing clinical trials for its Hemopurifier device.

Summary

• Aethlon Medical, Inc. reported a net loss of $5.37 million for the six months ended September 30, 2024, compared to a net loss of $6.32 million for the same period in 2023.
• The company's operating expenses decreased to $5.52 million for the six months ended September 30, 2024, from $6.58 million in the same period of 2023, primarily due to lower professional fees and general and administrative costs.
• Aethlon completed a public offering in May 2024, raising approximately $3.5 million in net proceeds, and an additional $1.84 million from warrant exercises in June 2024.
• As of September 30, 2024, the company had a cash balance of $6.86 million and working capital of $4.81 million.
• The company is conducting safety, feasibility, and dose-finding clinical trials for its Hemopurifier device in Australia and India for cancer patients.
• The first two patients in the Australian trial have successfully completed screening and are advancing to the run-in period.
• Aethlon is also pursuing clinical trials for the Hemopurifier in the treatment of severe COVID-19 in India, with one patient treated to date.
• The company is exploring the potential of the Hemopurifier in organ transplantation, specifically for removing harmful substances from recovered kidneys.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and a reduction in losses, the company's financial situation is precarious, with a need for significant additional funding and a material weakness in internal controls. This creates a cautious outlook.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Operating expenses were reduced due to lower professional fees and general and administrative costs.
• A successful public offering and warrant exercises provided a significant cash infusion.
• Clinical trials for the Hemopurifier are progressing in multiple countries.
• The first two patients in the Australian cancer trial have successfully completed screening.
• The company is exploring new applications for the Hemopurifier in organ transplantation.

Negatives

• The company continues to incur significant losses and negative cash flows.
• Aethlon has a material weakness in internal control over financial reporting.
• The company's existing cash is not expected to be sufficient to fund operations for the next twelve months.
• The company is dependent on raising additional capital to continue operations.
• There is no guarantee that the company will be able to raise additional capital on favorable terms.
• The company's patents may expire before FDA approval is obtained.

Risks

• The company faces risks related to its ability to raise additional capital to fund operations.
• There is a risk that the company may not be able to achieve commercial viability for its products.
• The company is subject to intense competition in the medical device industry.
• The company's Hemopurifier technology may become obsolete.
• Delays in clinical trials could jeopardize the company's ability to obtain regulatory approval.
• The company's common stock may be delisted from the Nasdaq Capital Market if it fails to regain compliance with listing requirements.
• The company is monitoring the impact of inflation, the war between Russia and Ukraine, and the military conflicts in Israel on its business.

Future Outlook

The company expects to continue to incur increasing negative cash flows and net losses for the foreseeable future and will need to raise additional capital through equity and/or debt financing. They plan to expand their operations, which may strain their resources. The company is also monitoring the impact of global events on its business and access to capital.

Management Comments

• The enrollment of the first two eligible patients marks a significant milestone in advancing our clinical program for the Hemopurifier.
• Management expects that existing cash as of September 30, 2024 will not be sufficient to fund the Company's operations for at least twelve months from the issuance date of these condensed consolidated financial statements.

Industry Context

Aethlon Medical is operating in the competitive medical device industry, focusing on innovative therapies for cancer and viral infections. The company's focus on exosome removal and its breakthrough device designation from the FDA position it as a potential disruptor in these fields. The company is also exploring the use of its technology in organ transplantation, which is an area of significant unmet need.

Comparison to Industry Standards

• Aethlon's financial results show a decrease in net loss compared to the previous year, which is a positive sign, but the company is still operating at a loss, which is common for clinical-stage biotech companies.
• The company's cash burn rate is significant, and it will need to raise additional capital to continue operations, which is a typical challenge for companies in this sector.
• The company's clinical trial progress is a key indicator of its potential, and the successful enrollment of patients in the Australian trial is a positive development.
• Compared to other companies in the medical device space, Aethlon is still in the early stages of development and commercialization, and its success will depend on the results of its clinical trials and its ability to secure regulatory approvals.
• Companies like Baxter International and Fresenius Medical Care are established players in the medical device industry, but Aethlon is focused on a niche area with its Hemopurifier technology.

Management Changes

Related Party Transactions

• The company accrued $68,250 for board fees and paid fees of $68,250 owed to non-employee directors for services in the current and prior quarter.
• The company accrued $455,397 for salary and related expenses associated with a Separation Agreement with a former employee.
• The company accrued $27,688 in health insurance costs related to the Separation Agreement.
• The company paid out $199,909 and $324,202 in separation expenses in the threeand six-months ended September 30, 2024, respectively.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential future equity offerings.
• Employees may be affected by potential future workforce reductions.
• Customers and patients may benefit from the development of the Hemopurifier, but its success is not guaranteed.
• Suppliers and creditors may be impacted by the company's financial instability.

Next Steps

• Continue clinical trials for the Hemopurifier in Australia and India.
• Complete necessary logistical steps to open the Indian clinical trial site for patient enrollment.
• Explore the potential of the Hemopurifier in organ transplantation.
• Seek additional financing to fund operations and clinical trials.
• Remediate the material weakness in internal control over financial reporting.

Key Dates

Keywords

Hemopurifier, clinical trials, cancer, COVID-19, organ transplantation, medical device, immunotherapeutic, exosomes, FDA, public offering, warrants, financial results